ISRG stock forecast, quote, news & analysis
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery... Show more
Intuitive Surgical (ISRG) Stock Analysis: Procedure Growth and AI Expansion Anchor a Steady Rebound
Key Takeaways
- Intuitive Surgical shares have climbed roughly 8.5% over the trailing 30 days, a meaningful rebound for a stock still down about 25% year to date.
- The advance coincided with a busy stretch of analyst price-target revisions ahead of third-quarter results, with several firms maintaining constructive ratings.
- Core fundamentals remain intact: worldwide da Vinci and Ion procedures grew about 16% year over year in the second quarter of 2026.
- Recurring revenue from instruments, accessories, and services continues to anchor the business model and support margins.
- Key watch items include third-quarter earnings, U.S. procedure momentum, and the company's early push into GI care and AI-driven digital tools.
Current Market Snapshot
Intuitive Surgical (ISRG) shares have shown a measured recovery in recent weeks, moving from roughly $393 in mid-September to near $427 by mid-October, an increase of about 8.5%. That rebound stands out against a broader 2026 backdrop in which the stock has declined roughly 25% since the start of the year, even as underlying operating performance has remained strong. The stock trades at a premium forward price-to-earnings multiple, reflecting its status as a high-growth medical-technology leader rather than a conventional value holding. Investor sentiment appears cautiously constructive, with several Wall Street firms revisiting price targets in early October and the market looking ahead to the company's next quarterly report.
Intuitive Surgical (ISRG) Business Overview and Competitive Position
Intuitive Surgical, headquartered in Sunnyvale, California, is the pioneer and global leader in robotic-assisted minimally invasive surgery. Its core da Vinci platform is used across urology, gynecology, general surgery, and thoracic procedures, while the Ion endoluminal system extends the company into robotic-assisted lung biopsy. The newer da Vinci 5 and single-port (SP) systems are central to the company's current product cycle, supported by digital tools such as the My Intuitive+ app and AI-enabled case insights.
Intuitive's economic model is built on a growing installed base and a highly recurring revenue stream. Instruments and accessories account for roughly 60% of sales, with systems and services making up most of the remainder. This "razor-and-blade" structure, combined with a dominant share of the robotic-surgery market, gives the company pricing power and visibility that few medical-device peers such as Medtronic (MDT) can match. Investors follow the stock closely because procedure volume, system placements, and the expansion of the installed base directly drive both near-term results and long-term value.
Recent Developments Driving ISRG
Much of the recent price action has been shaped by a cluster of analyst actions and positioning ahead of third-quarter earnings. In early October, Citi maintained a Buy rating with a $500 target, RBC Capital reiterated Buy at $575, and Barclays initiated coverage with an Overweight rating and a $485 target. Later in the month, Leerink Partners raised its target to $473, Mizuho lifted its target to $415 while keeping a Neutral rating, BTIG lowered its target to $454 while keeping Buy, and Baird raised its target to $513. The mixed but generally constructive tone reflects both confidence in procedure growth and caution about U.S. volume headwinds tied to Affordable Care Act and Medicaid changes.
On the product front, management disclosed on its second-quarter earnings call that it had submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, an early step toward expanding beyond surgery and lung diagnostics into gastrointestinal care. The company has also been deepening its presence in China, with Executive Chair Gary Guthart outlining plans for clinical training, supply-chain relationships, and digital and AI collaboration, alongside a planned showcase of the da Vinci 5 and SP systems at the China International Import Expo in November.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies drawn from a much larger universe of AI-powered bots. While Tickeron offers hundreds of AI trading bots that monitor thousands of tickers across the market, only the top-performing and most relevant strategies are surfaced in this section, helping traders cut through the noise. These bots vary considerably in approach, timeframe, and performance metrics, so users can evaluate strategies that align with their own trading style and risk tolerance. Exploring the page can offer a practical starting point for investors interested in algorithmic approaches to markets like the healthcare and robotics sector.
2026 Outlook and What Investors Should Watch
Intuitive Surgical's 2026 outlook remains anchored to procedure growth, with management guiding to worldwide da Vinci procedure growth of approximately 13.5% to 15.5%. The continued global rollout of da Vinci 5, broader availability of force-feedback instruments, steady Ion adoption, and the SP stapler's expansion all support that trajectory. Longer term, the company's digital and AI roadmap, including telepresence, telesurgery, and deeper decision support, represents an emerging value layer beyond hardware.
Investors should monitor several factors in the months ahead. U.S. procedure momentum, particularly in bariatrics where GLP-1 weight-loss drugs have pressured volumes, remains a key swing factor. Competitive dynamics are also evolving, with Johnson & Johnson (JNJ) advancing its own FDA-authorized soft-tissue robotics platform. International headwinds in China and Japan, tariff effects on gross margin, and the stock's premium valuation all carry risk. None of these factors point to a single defined outcome, and investors should weigh them against the company's demonstrated ability to compound procedure growth and recurring revenue.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for ISRG turns positive, indicating new upward trend
ISRG saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 58 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 210 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 170 of 264 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 13 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 35%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for ISRG turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 31 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.400) is normal, around the industry mean (4.882). P/E Ratio (48.870) is within average values for comparable stocks, (38.076). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How can one grasp Binary Options in an international context beyond the U.S.?
What Is a Data Analyst?
Tickeron Unveils AI Trading Bot with 85% Win Rate for Tech and Semiconductor Stocks
Walmart (WMT) Stock Analysis: Market Movements, Financial Performance, and AI-Driven Insights as of May 20, 2025
FAQ: What features or products would you recommend me as a swing trader?
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther